
From: Charles Kandziolka <charles.kandziolka@bayer.com>
Sent: Friday, January 11, 2019 11:11 AM
To: AGO - High Cost Prescription Drugs
Subject: Vitrakvi® (larotrectinib)

Hello,

Pursuant to 18 V.S.A. § 4637, Bayer is notifying the Vermont Attorney General's Office that the introductory wholesale acquisition cost of Vitrakvi® (larotrectinib) is in excess of the Medicare Part D specialty drug threshold.

Product	NDC	WAC
Vitrakvi (larotrectinib) 25 mg Capsule	71777-390-01	\$ 10,933.33
Vitrakvi (larotrectinib) 100 mg Capsule	71777-391-01	\$ 32,800.00
Vitrakvi (larotrectinib) 20mg/mL Oral Solution	71777-392-01	\$ 14,577.78

Vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:

- have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment.

The marketing and pricing plans are not publicly available. We estimate that approximately 2,500-3,000 patients in the US may be prescribed Vitrakvi. Vitrakvi was granted Priority Review and Breakthrough Therapy Designation. On November 14, 2017 Bayer entered into an agreement with Loxo Oncology to develop and commercialize larotrectinib worth up to \$1.35B.

Kind regards,

Charles Kandziolka
Strategic Pricing & Reimbursement

Bayer: Science For A Better Life

Bayer U.S. Market Access
100 Bayer Boulevard, PO Box 915
Building B200, 2B4234
Whippany, NJ 07981-0915, USA
Tel: (862) 404-4802
Mobile: (862) 812-9702
E-mail: charles.kandziolka@bayer.com